Advanced search
Start date
Betweenand

Pre-clinical studies of non-invasive treatments in leishmaniasis

Abstract

Leishmaniasis are infectious diseases caused by protozoal belonging to the Leishmania genus. Different species are pathogenic, and cause distinct clinical forms in humans, some of them are considered severe forms, such as visceral and anergic diffuse leishmaniasis. Pentavalent antimonials and amphotericin B are the main drugs employed in the therapy, however, are outdated, the injection is painful and they induce local and systemic side effects in patients (leading to the therapy abandon), and yet resistant parasites have been found. Based on these, it is important and urgent to characterize new drugs, as well as new ways to treat patients with this important neglected tropical disease. This group has been characterizing the leishmanicidal action of different molecules (natural or synthetic), and some of them showed to be promising in vivo. Thus, aiming at improve their efficacies and following the recommendations of DNDi this project proposes to study the therapeutic action of butenafine, buparvaquone, 5-chloro-8-hydroxyquinoline, 7-Bromo-5-iodoquinolin-8-yl acetate and ursolic acid formulated to dermatological creams or nanosystems to treat topically or orally experimental animals with cutaneous or visceral leishmaniasis. To evaluate the efficacy of nanoformulations, cutaneous or visceral parasitism will be analyzed, furthermore histopathological and immunological changes will be recorded. All these modifications will be compared to those of animals treated with Glucantime. The toxicity of studied formulations will be evaluated using histopathological studies in target organs, as well as biochemical alterations. (AU)

Articles published in Agência FAPESP Newsletter about the research grant:
Articles published in other media outlets (0 total):
More itemsLess items
VEICULO: TITULO (DATA)
VEICULO: TITULO (DATA)

Scientific publications (6)
(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)
BEZERRA-SOUZA, ADRIANA; JESUS, JESSICA A.; LAURENTI, MARCIA D.; LALATSA, AIKATERINI; SERRANO, DOLORES R.; PASSERO, LUIZ FELIPE D.. Nanoemulsified Butenafine for Enhanced Performance against Experimental Cutaneous Leishmaniasis. JOURNAL OF IMMUNOLOGY RESEARCH, v. 2021, . (16/00468-0, 18/24077-6, 17/09405-4)
JESUS, JESSICA ADRIANA; FRAGOSO DA SILVA, THAYS NICOLLI; YAMAMOTO, EDUARDO SEIJI; G. LAGO, JOAO HENRIQUE; DALASTRA LAURENTI, MARCIA; PASSERO, LUIZ FELIPE DOMINGUES. Ursolic Acid Potentializes Conventional Therapy in Experimental Leishmaniasis. PATHOGENS, v. 9, n. 10, . (18/24077-6, 18/07885-1, 16/00468-0, 16/10324-6)
JESUS, JESSICA ADRIANA; SOUSA, ILZA MARIA OLIVEIRA; DA SILVA, THAYS NICOLLI FRAGOSO; FERREIRA, AUREA FAVERO; LAURENTI, MARCIA DALASTRA; ANTONANGELO, LEILA; FARIA, CAROLINE SILVERIO; DA COSTA, PAULO CARDOSO; DE CARVALHO FERREIRA, DOMINGOS; PASSERO, LUIZ FELIPE DOMINGUES. Preclinical Assessment of Ursolic Acid Loaded into Nanostructured Lipid Carriers in Experimental Visceral Leishmaniasis. PHARMACEUTICS, v. 13, n. 6, . (18/04080-2, 16/10324-6, 18/24077-6, 16/00468-0)
DEMATEI, ANDERSON; NUNES, JOAO B.; MOREIRA, DANIEL C.; JESUS, JESSICA A.; LAURENTI, MARCIA D.; MENGARDA, ANA C. A.; VIEIRA, MARIA SILVA; DO AMARAL, CONSTANCA PAIS; DOMINGUES, MARCO M.; DE MORAES, JOSUE; et al. Mechanistic Insights into the Leishmanicidal and Bactericidal Activities of Batroxicidin, a Cathelicidin-Related Peptide from a South American Viper (Bothrops atrox). Journal of Natural Products, v. 84, n. 6, p. 1787-1798, . (19/25905-2, 18/24077-6, 16/22488-3)
PAROLIN, GIOVANA A.; PASSERO, LUIZ FELIPE D.; LAGO, JOAO HENRIQUE G.; PERES, LAURA OLIVEIRA. Antileishmanial activity evaluation of poly(thymolformaldehyde)-A biobased material from thymol. INDUSTRIAL CROPS AND PRODUCTS, v. 171, . (18/07885-1, 18/24077-6, 18/18180-9, 14/50869-6)
PASSERO, LUIZ FELIPE DOMINGUES; CAVALLONE, ITALO NOVAIS; BELDA JR, WALTER. Reviewing the Etiologic Agents, Microbe-Host Relationship, Immune Response, Diagnosis, and Treatment in Chromoblastomycosis. JOURNAL OF IMMUNOLOGY RESEARCH, v. 2021, . (18/24077-6)

Please report errors in scientific publications list by writing to: cdi@fapesp.br.